North Carolina Medicaid waiver approves VR therapy reimbursement for neurodivergent residents, signaling public-payer adoption of digital therapeutics
Executive summary: North Carolina approved Medicaid reimbursement for Floreo's VR therapy platform under the NC Innovations Waiver for neurodivergent residents in Alliance Health's seven-county region. Demonstrates public-payer willingness to cover prescription digital therapeutics for neurodevelopmental conditions, potentially setting precedent for other state Medicaid programs and commercial insurers.
Who is involved: North Carolina Medicaid, NC Innovations Waiver program, Alliance Health (managed care organization), Floreo (VR therapy provider), neurodivergent residents and families.
Likely next: Expansion to additional counties/regions, other state Medicaid waivers evaluating similar coverage, Floreo seeking additional state approvals, potential private payer follow-on.
North Carolina's NC Innovations Waiver now covers Floreo's VR therapy platform for neurodivergent residents in Alliance Health's seven-county region. This marks a notable step in Medicaid reimbursement for prescription digital therapeutics, moving VR-based behavioral therapy from pilot programs into covered benefits. The decision could influence other state waivers and private payer policies for digital health interventions targeting autism and neurodevelopmental conditions.
Timeline
- — Daniel Ek-founded Neko Health tops latest Sifted ranking (Sifted — EU startups)
- — North Carolina Approves Reimbursement of VR Therapy for Neurodivergent Residents Under NC Innovations Waiver (PR Newswire)
Analysis — what this means
Likely next events
- Floreo to pursue additional state Medicaid waiver approvals in Q4 2026
- CMS may issue guidance on VR/digital therapeutic reimbursement under HCBS waivers
- Alliance Health to report utilization and outcomes data by mid-2027
Sectors affected
- Digital therapeutics (VR-based behavioral therapy)
- Medicaid home and community-based services (HCBS)
- Autism/neurodevelopmental disorder care management
Regulatory implications
- Precedent for state Medicaid waivers covering prescription digital therapeutics under 1915(c) HCBS authority
- Potential CMS guidance on digital therapeutic reimbursement pathways
Historical parallels
- Akili Interactive's EndeavorRx FDA clearance (2020) and subsequent Medicaid coverage decisions
- Pear Therapeutics' reSET-O Medicaid coverage expansions (2021-2023)